Michael R. Harrison, MD
There are potential practice-changing regimens on the horizon following exciting findings from the CABOSUN and CheckMate-214 trials for patients with advanced renal cell carcinoma (RCC).
on Genitourinary Cancers, Harrison, an assistant professor of medicine, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discussed emerging data that are likely to impact the treatment landscape for patients with RCC.
OncLive: Can you please provide an overview of your presentation?
My talk covered the sequencing of therapies for RCC—not only in metastatic RCC, but also in the localized setting. I discussed the S-TRAC trial, which investigated sunitinib for high-risk localized RCC. I then discussed the randomized phase II CABOSUN trial, which investigated cabozantinib versus sunitinib in intermediate- and poor-risk patients with metastatic RCC who were previously untreated. Lastly, I focused on the CheckMate-214 trial investigating ipilimumab and nivolumab combined versus sunitinib also in the intermediate and poor-risk population that was previously untreated.
... to read the full story